How Language Develops, What Goes Wrong, And Why It Matters: Following The Early Language In Victoria Study To Age 13
Funder
National Health and Medical Research Council
Funding Amount
$857,242.00
Summary
One in five children start school with low language. Little is known about the long term effects on developmental, educational attainment and other outcomes later in life. In this landmark study we will track the children's language, literacy and wellbeing from ages 8 to 12 years. We will capture the children's ability as they finish their primary school education and prior to the crucial transfer to high school.
The Contribution Of Home Language Exposure To Intergenerational Transmission Of Inequality
Funder
National Health and Medical Research Council
Funding Amount
$1,281,706.00
Summary
The amount of language stimulation from parent to child could be the key driver behind intergenerational inequality. Children learn language through social interaction and this study will significantly enhance our current understanding of exposure to language in the child's home environment. The study will demonstrate how inequalities in the early years have far reaching consequences for later health and development.
Neurobiology Of Childhood Speech Disorders: Improving Detection, Diagnosis And Clinical Care
Funder
National Health and Medical Research Council
Funding Amount
$994,575.00
Summary
One in 20 children have a speech disorder at school entry, with lifelong deficits in psychosocial, academic and employment outcomes. Little is known about the aetiology of speech disorders, preventing targeted care. We combine expertise in speech pathology, gene discovery and brain imaging, to advance knowledge on gene and brain contributions to speech disorder. We will have direct impacts on clinical care including detection, diagnosis and counselling, optimising outcomes for affected children.
Targeted Development Of AMPK Β2-isoform Allosteric Activators
Funder
National Health and Medical Research Council
Funding Amount
$898,147.00
Summary
Sedentary lifestyles and consumption of high energy foods has led to dramatic increases in the incidence of diseases associated with metabolic dysregulation e.g. type 2 diabetes. An attractive drug target to treat these diseases is AMP-activated protein kinase (AMPK) which functions as a cellular fuel gauge. We have discovered a new drug that crucially activates the form of AMPK found in metabolically active organs. We aim to develop this drug to unlock new therapeutic opportunity.